Strides Shasun is currently trading at Rs. 957.60, up by 21.05 points or 2.25% from its previous closing of Rs. 936.55 on the BSE.
The scrip opened at Rs. 944.70 and has touched a high and low of Rs. 964.75 and Rs. 936.30 respectively. So far 16408 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1259.00 on 03-Feb-2017 and a 52 week low of Rs. 848.50 on 24-May-2017.
Last one week high and low of the scrip stood at Rs. 970.00 and Rs. 925.60 respectively. The current market cap of the company is Rs. 8428.12 crore.
The promoters holding in the company stood at 31.09%, while institutions and non-institutions held 48.89% and 20.02% respectively.
Strides Shasun has received approval from the United States Food & Drug Administration (USFDA) for Amantadine Hydrochloride Capsules USP, 100 mg. The product received approval in 15 months under the new GDUFA regime.
The US market for this product is around $25 million with three generic players, as per IMS data. The product will be launched immediately.
Strides Shasun (formerly known as Strides Arcolab) is engaged in manufacturing, sale and export of pharmaceutical products. It offers general tablets, hard gelatin and soft gelatin capsules, sachets, potent drugs and semi-solids.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: